Abstract
The mineralocorticoid receptor antagonist spironolactone (SPIR) reduces the mortality and morbidity in patients with congestive heart failure (CHF). Overexpression of proinflammatory cytokines contribute to the development and progression of CHF.
Originalsprog | Engelsk |
---|---|
Tidsskrift | Immunology Letters |
Vol/bind | 91 |
Udgave nummer | 2-3 |
Sider (fra-til) | 87-91 |
Antal sider | 5 |
ISSN | 0165-2478 |
DOI | |
Status | Udgivet - 15 feb. 2004 |